LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Lifevantage Corp revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protandim product line | $81.99M | $95.33M | $104.14M | $119.72M | $135.62M | $150.27M | $156.34M | $144.10M | $130.09M | $130.87M | 44.9% | -14.0% |
| TrueScience product line | $37.85M | $48.71M | $56.25M | – | – | – | – | – | – | – | 20.7% | -22.3% |
| LifeVantage product line | $32.26M | $61.33M | – | – | – | – | – | – | – | – | 17.7% | -47.4% |
| AXIO product line | $15.01M | $15.31M | $13.38M | – | – | – | – | – | – | – | 8.2% | -2.0% |
| LoveBiome Product Line | $9.12M | $0 | – | – | – | – | – | – | – | – | 5.0% | – |
| Other | $4.40M | $5.73M | $4.50M | $44.18M | $47.87M | $47.29M | $52.84M | $57.01M | $52.23M | $44.18M | 2.4% | -23.3% |
| PhysIQ product line | $3.80M | $5.10M | $3.83M | – | – | – | – | – | – | – | 2.1% | -25.5% |
| Petandim product line | $1.96M | $2.12M | $2.40M | – | – | – | – | – | – | – | 1.1% | -7.4% |
| Other | – | – | – | – | – | – | – | – | $47.62M | $44.18M | – | – |
| LifeVantage TrueScience Skin Care Regimen | – | $56.23M | $15.68M | $49.49M | $22.88M | $22.62M | $23.74M | $24.85M | $20.88M | $24.44M | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $135.40M | $178.44M | $145.68M | $148.52M | $130.93M | $144.90M | $155.48M | $151.97M | $142.45M | $144.84M | 74.2% | -24.1% |
| Non-US | $47.18M | $50.09M | $54.49M | – | – | – | – | – | – | – | 25.8% | -5.8% |
| Japan | $24.15M | $25.39M | $26.99M | $32.08M | $36.81M | $41.17M | $42.34M | $40.80M | $41.84M | $39.39M | 13.2% | -4.9% |
| Other foreign markets | $23.03M | $24.69M | $27.50M | – | – | – | – | – | – | – | 12.6% | -6.7% |
| Americas | – | – | $152.91M | $155.36M | $138.32M | $154.66M | $166.34M | $163.24M | $151.61M | $150.84M | – | – |
| Asia/Pacific & Europe | – | – | $47.26M | $58.04M | $68.04M | $65.53M | $66.58M | $62.72M | $51.60M | $48.65M | – | – |
From the segment and revenue-disaggregation notes of Lifevantage's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.